Abbreviated name: DRV
Synonyms: Prezista® | TMC114 | UIC-94017
darunavir is an approved drug (FDA (2006), EMA (2007))
Compound class:
Synthetic organic
Comment: Darunavir is a second-generation human immunodeficiency virus 1 (HIV-1) protease inhibitor (PI) [2].
![]() View more information in the IUPHAR Pharmacology Education Project: darunavir |
|
No information available. |
Summary of Clinical Use ![]() |
Darunavir is used in the treatment of HIV-1 infection and for postexposure prophylaxis (off-label). To increase its bioavailability and half-life, darunavir is coadministered with other antiretroviral agents such as ritonavir or cobicistat. The compound is also approved as a component of Symtuza®, a once daily anti-HIV therapy that contains darunavir, cobicistat, emtricitabine, and tenofovir alafenamide fumarate. SARS-CoV-2 and COVID-19: The antiviral activity and safety of darunavir/cobicistat for treating COVID-19 pneumonia has been evaluated in a Phase 3 clinical trial (NCT04252274). This trial found no significant benefit for patients with severe COVID-19, when compared to standard therapy [1]. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT04252274 | Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19 | Phase 3 Interventional | Shanghai Public Health Clinical Center |
External links ![]() |
For extended ADME data see the following: Electronic Medicines Compendium (eMC) Drugs.com European Medicines Agency (EMA) |